These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31901668)

  • 21. Clinical experience on the use of perampanel in epilepsy among child neurologists in the Philippines.
    Macrohon B; Janette Resurreccion-De La Calzada J; Sanchez-Gan B
    Brain Dev; 2021 Mar; 43(3):411-418. PubMed ID: 33272774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences.
    Biró A; Stephani U; Tarallo T; Bast T; Schlachter K; Fleger M; Kurlemann G; Fiedler B; Leiz S; Nikanorova M; Wolff M; Müller A; Selch C; Staudt M; Kluger G
    Neuropediatrics; 2015 Apr; 46(2):110-6. PubMed ID: 25730374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
    Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
    Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study.
    Shah E; Reuber M; Goulding P; Flynn C; Delanty N; Kemp S
    Seizure; 2016 Jan; 34():1-5. PubMed ID: 26615577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
    Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
    Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and tolerability of adjunctive perampanel in pediatric patients (aged 4-12 years) with refractory epilepsy: An observational study.
    Chu SJ; Li Y; Tang JH
    Medicine (Baltimore); 2022 Nov; 101(45):e31408. PubMed ID: 36397377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome.
    Yoshitomi S; Takahashi Y; Yamaguchi T; Imai K; Ishii A; Hirose S; Inoue Y
    Epilepsy Res; 2019 Aug; 154():34-38. PubMed ID: 31035242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of perampanel in patients with intellectual disability and epilepsy.
    Snoeijen-Schouwenaars FM; van Ool JS; Tan IY; Schelhaas HJ; Majoie MH
    Epilepsy Behav; 2017 Jan; 66():64-67. PubMed ID: 28038388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
    Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
    Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: A single center prospective observational study.
    Rosati A; Boncristiano A; Doccini V; Pugi A; Pisano T; Lenge M; De Masi S; Guerrini R
    Epilepsia; 2019 Nov; 60(11):2255-2262. PubMed ID: 31630399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.
    Rektor I; Krauss GL; Bar M; Biton V; Klapper JA; Vaiciene-Magistris N; Kuba R; Squillacote D; Gee M; Kumar D
    Acta Neurol Scand; 2012 Oct; 126(4):263-9. PubMed ID: 22913800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
    Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
    J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase IV PROVE study: Perampanel in real-world clinical care of pediatric patients with epilepsy.
    Moretz K; Wheless J; Santos C; Segal E; Lancman M; Patten A; Malhotra M
    Eur J Paediatr Neurol; 2024 May; 50():23-30. PubMed ID: 38569352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study.
    Qu R; Dai Y; Chen X; Li R; Liu M; Zhu Y
    Epileptic Disord; 2021 Dec; 23(6):854-864. PubMed ID: 34730518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.